Kairos Pharma, Ltd. Common Stock (KAPA)
0.7200
-0.0900 (-11.11%)
NYSE · Last Trade: Dec 13th, 8:28 PM EST
Detailed Quote
| Previous Close | 0.8100 |
|---|---|
| Open | 0.7800 |
| Bid | 0.6700 |
| Ask | 0.7900 |
| Day's Range | 0.7200 - 0.8230 |
| 52 Week Range | 0.4000 - 3.250 |
| Volume | 317,943 |
| Market Cap | 14.99M |
| PE Ratio (TTM) | -2.323 |
| EPS (TTM) | -0.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 150,391 |
Chart
News & Press Releases
Via Benzinga · November 11, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, released a Letter to Shareholders from CEO John Yu, M.D., outlining 2025 accomplishments and the outlook for 2026. The Company reported positive interim safety and efficacy results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer, showing clinical benefit in 86% of treated patients, with durable progression-free survival and no dose-limiting toxicities. The findings, presented at the European Society for Medical Oncologists Meeting, suggest ENV105 may extend the effectiveness of standard care while maintaining strong tolerability. Kairos continues patient recruitment, with enrollment expected to reach 100 across leading U.S. cancer centers.
Via Investor Brand Network · November 4, 2025
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below.
By Kairos Pharma Ltd · Via Business Wire · November 4, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) in men with metastatic castration-resistant prostate cancer. Presented at the European Society for Medical Oncology meeting in Berlin, the study showed clinical benefit in 86% of patients treated with ENV-105 combined with apalutamide, with all responders remaining progression-free for at least four months and half beyond one year. Seven of nine evaluable patients experienced PSA reductions, supporting the therapy’s potential to restore hormone responsiveness. The randomized trial, led by Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy.
Via Investor Brand Network · October 20, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany.
By Kairos Pharma, Ltd · Via Business Wire · October 20, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos’s presentation, titled, “Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer” will take place in Berlin, Germany on October 17–21, 2025.
By Kairos Pharma, Ltd · Via Business Wire · October 7, 2025
Via Benzinga · September 19, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 19, 2025
Via Benzinga · September 19, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · September 18, 2025
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · September 18, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. Among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, with five patients still on treatment and seven of nine showing declines in prostate-specific antigen levels. This exceeded the trial’s target of a 45% improvement in progression-free survival compared with the standard 3.7 months for second- or third-line hormone therapy. The treatment was well tolerated with no dose-limiting toxicities observed. Kairos is hosting a KOL webcast today at 5 p.m. ET / 2 p.m. PT to review the findings with clinical experts.
Via Investor Brand Network · September 18, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Kairos Pharma is hosting a virtual KOL (key opinion leader) event to provide perspectives on this data at 5 p.m. ET / 2 p.m. PT today. Interested participants can sign-up to receive the webcast link here.
By Kairos Pharma, Ltd · Via Business Wire · September 18, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced it will host a key opinion leader event on Sept. 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu said the event will highlight safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives underscoring the compound’s potential role in addressing cancer drug resistance.
Via Investor Brand Network · September 11, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested participants can sign-up to receive the webcast link here.
By Kairos Pharma, Ltd · Via Business Wire · September 11, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, being held Sept. 8–10, 2025, at the Lotte New York Palace Hotel in New York.
Via Investor Brand Network · September 3, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Initial Phase 1 Data of ENV105 at World Lung Cancer Conference
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp at the World Lung Cancer Conference, taking place Sept. 6–9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp’s presentation, titled “Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients,” highlights the combination therapy of ENV105 with osimertinib, with the open-label trial’s primary objective being to evaluate safety and tolerability.
Via Investor Brand Network · September 3, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.
By Kairos Pharma, Ltd · Via Business Wire · September 3, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
By Kairos Pharma, Ltd · Via Business Wire · September 2, 2025
Via Benzinga · September 2, 2025
Via Benzinga · July 30, 2025
Via Benzinga · July 17, 2025
Via Benzinga · July 16, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · July 16, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The company will host one-on-one meetings and deliver a presentation available virtually via kairospharma.com.
Via Investor Brand Network · July 16, 2025